Biostem Technologies

Biostem Technologies EBIT Growth

The Year-over-Year EBIT Growth of Biostem Technologies (BSEM) as of Nov 19, 2026 is 500.90 %. In the previous year, Year-over-Year EBIT Growth was -66.24 % — a change of -856.18% (higher).

EBIT Growth

500.90 %

YoY

-856.18%

Last updated:

Year-over-Year EBIT Growth of Biostem Technologies is 2024 500.90 % . Year-over-Year EBIT Growth of Biostem Technologies was 2023 -66.24 % . It decreases by -856.18% higher compared to the previous year.

The Biostem Technologies EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2017
-29.34 USD
Jan 1, 2018
-60.87 USD
Jan 1, 2019
26.92 USD
Jan 1, 2020
67.54 USD
Jan 1, 2021
12.84 USD
Jan 1, 2022
-191.56 USD
Jan 1, 2023
-66.24 USD
Jan 1, 2024
500.90 USD
The Biostem Technologies EBIT Growth history
YEAREBIT GrowthYoY
500.90 %-856.18%
-66.24 %-65.42%
-191.56 %-1,591.81%
12.84 %-80.99%
67.54 %+150.88%
26.92 %-144.23%
-60.87 %+107.44%
-29.34 %-49.48%
-58.08 %-95.03%
-1,168.61 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biostem Technologies Stock analysis

What does Biostem Technologies do? Biostem Technologies Inc is a US company specializing in regenerative medicine. It was founded in 2007 and is based in Clearwater, Florida. Biostem Technologies is listed on the OTCQB Stock Exchange and offers a wide range of products in the field of regenerative medicine. The company's business model primarily involves advancing growth in the field of regenerative medicine through the development and marketing of new products and technologies. They focus on the production of stem cells that can be used in the regeneration of damaged tissues and organs. They also offer research and development of stem cell therapies, manufacturing of stem cell products, and related services. Biostem Technologies places emphasis on processing umbilical cord blood stem cells, collaborating with medical facilities to collect and isolate these cells for preservation. The company has also developed products such as BioStem Serum and BioStem Gel, made from stem cells and used in regeneration and wound healing. They have developed technologies for regenerating damaged tissues and organs, including a technology for regenerating muscle and adipose tissue through stem cell injection. Clinical studies have shown promising results with this technology. Biostem Technologies has partnerships with other companies and institutes in the field of regenerative medicine, including working with the National Institute of Neurological Disorders and Stroke to develop a new therapy for multiple sclerosis. They also provide consulting services to assist other companies in developing regenerative products and services. In conclusion, Biostem Technologies is a leading company in the field of regenerative medicine and stem cell therapies, offering a range of products and services. They also provide important technologies for tissue regeneration, positioning them as a key player in the field of regenerative medicine. Biostem Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biostem Technologies stock

Year-over-Year EBIT Growth of Biostem Technologies is 500.90 % in 2024.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Biostem Technologies since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Biostem Technologies historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Biostem Technologies

All Key Metrics — Biostem Technologies